JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib

Table 5

Patient characteristics and JAK2 levels stratified by the presence of early molecular response groups.

Variable	Early molecular response
	Present (n = 24)	Absent (n = 16)	p-Value
Age, years (mean ± SD)	40 ± 12	40 ± 10	0.986
Sex, n (%)	—	—	0.792
Male	14 (58.3)	10 (62.5)	—
Female	10 (41.7)	6 (37.5)	—
Spleen size, cm (mean ± SD)	9 ± 3	7 ± 2	0.104
Laboratory parameters, mean ± SD, or median (range)
Hemoglobin (g/dL)	9.4 ± 2.1	9.5 ± 3.2	0.892
White blood cells (/μL)	100,150 (20,390–498,470)	131,475 (33,000–344,130)	0.456
Peripheral blood basophils (%)	1 (0–8)	1 (0–7)	0.836
Eosinophils (%)	1 (0–5)	1 (0–5)	0.614
Platelet count (x10^3/μL)	199 (31–803)	462 (49–1,123)	0.024
Peripheral blood blasts (%)	8 (4–19)	9 (2–20)	0.709
Sokal risk groups, n (%)	—	—	0.936
Low (<0.8)	10 (41.7)	7 (43.8)	—
Intermediate (0.8–1.2)	4 (16.6)	3 (18.8)	—
High (>1.2)	10 (41.7)	6 (37.4)	—
Hasford risk groups, n (%)	—	—	0.987
Low (≤780)	7 (29.2)	5 (31.3)	—
Intermediate (781–1,480)	9 (37.5)	6 (37.4)	—
High (>1,480)	8 (33.3)	5 (31.3)	—
EUTOS risk groups, n (%)	—	—	0.154
Low risk (≤87)	24 (100.0)	14 (87.5)	—
High risk (>87)	0 (0.0)	2 (12.5)	—
JAK2 levels before imatinib treatment, median (range)
JAK2 gene (fold changes)	14.35 (0.18–35.13)	43.86 (9.78–100.40)	<0.001
Phosphorylated JAK2 (U/mL)	0.40 (0.03–0.90)	0.80 (0.24–1.34)	0.005
Total JAK2 (pg/mL)	61.07 (11.82–370.79)	451.66 (45.98–2,291.00)	0.002
JAK2 levels after 3 months of imatinib treatment, median (range)
JAK2 gene (fold changes)	0.70 (0.00–8.00)	1.20 (0.00–39.00)	0.422
Phosphorylated JAK2 (U/mL)	0.28 (0.01–1.10)	0.80 (0.24–13.95)	0.001
Total JAK2 (pg/mL)	23.17 (2.92–282.50)	26.64 (5.49–461.89)	0.804